Fetal hemoglobin in sickle cell anemia: a glass half full?
The DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index.
Abstract
Fetal hemoglobin (HbF) modulates the phenotype of sickle cell anemia by inhibiting deoxy sickle hemoglobin (HbS) polymerization. The blood concentration of HbF, or the number of cells with detectable HbF (F-cells), does not measure the amount of HbF/F-cell. Even patients with high HbF can have severe disease because HbF is unevenly distributed among F-cells, and some cells might have insufficient concentrations to inhibit HbS polymerization. With mean HbF levels of 5%, 10%, 20%, and 30%, the distribution of HbF/F-cell can greatly vary, even if the mean is constant. For example, with 20% HbF, as few as 1% and as many as 24% of cells can have polymer-inhibiting, or protective, levels of HbF of ∼10 pg; with lower HbF, few or no protected cells can be present. Only when the total HbF concentration is near 30% is it possible for the number of protected cells to approach 70%. Rather than the total number of F-cells or the concentration of HbF in the hemolysate, HbF/F-cell and the proportion of F-cells that have enough HbF to thwart HbS polymerization is the most critical predictor of the likelihood of severe sickle cell disease.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“This is consistent with disease severity in most patients with these HbF levels and individuals with Bantu/Benin/Cameroon haplotypes.”
From Fetal hemoglobin in sickle cell anemia (2020) · cites this paper as [52]
In the citing paper
“It is nearly impossible to have a clinically important number of fully protected F-cells when HbF is 5%; no more than 15% of cells can be protected when HbF is 10%.52”
From Fetal hemoglobin in sickle cell anemia (2020) · cites this paper as [52]
In the citing paper
“When HbF is near 30%, disease can be relatively benign and 70% of cells can be protected.[52][53][54]”
From Fetal hemoglobin in sickle cell anemia (2020) · cites this paper as [52]
In the citing paper
“Consistent with the phenotype of most patients with natural or therapy-induced HbF levels of 20%, it is possible for nearly 25% of F-cells to have polymer-inhibiting HbF levels.”
From Fetal hemoglobin in sickle cell anemia (2020) · cites this paper as [52]
Citations
Cites
Mortality in sickle cell disease. Life expectancy and risk factors for early death
Platt, O. S., Brambilla, D. J., Rosse, W. F., Milner, P. F., Castro, O., Steinberg, M. H., & Klug, P. P. (1994) · New England Journal of Medicine · doi:10.1056/nejm199406093302303 · Cited by 3,320 · cited 2×
“Different concentrations of HbF were postulated to protect against different complications of disease, although 1 study suggested that any increment in HbF was associated with longevity.(22,25) Only the calculated mean value of HbF/F-cell was reported and only in some of these studies.”
Self-citationSteinberg, M. H., Barton, F., Castro, O., Pegelow, C. H., Ballas, S. K., Kutlar, A., Orringer, E., Bellevue, R., Olivieri, N., Eckman, J., et al. (2003) · JAMA · doi:10.1001/jama.289.13.1645 · Cited by 931 · cited 1×
“Patients are better and probably live longer, but they are rarely asymptomatic, especially when this drug is started in adults after HbF levels stabilize.(19,20) HbF is heterocellularly distributed when high levels are successfully induced with hydroxyurea.”
Self-citationKato, G. J., Gladwin, M. T., & Steinberg, M. H. (2007) · Blood Reviews · doi:10.1016/j.blre.2006.07.001 · Cited by 876 · cited 1×
“Lysis of these cells release heme products into the circulation that scavenge nitric oxide and permit the development of endothelial damage and other consequences of reduced nitric oxide bioavailability.(24) It is also possible that the pathophysiology of some hemolysis-associated complications is less dependent on Hb…”
Self-citationHandbook of Beta Distribution and Its Applications
(2004) · CRC Press eBooks · doi:10.1201/9781482276596 · Cited by 644
Fetal hemoglobin in sickle cell anemia
Akinsheye, I., Alsultan, A., Solovieff, N., Ngo, D., Baldwin, C. T., Sebastiani, P., Chui, D. H. K., & Steinberg, M. H. (2011) · Blood · doi:10.1182/blood-2011-03-325258 · Cited by 553 · cited 1×
“Adult patients with sickle cell anemia who have the AI haplotype have HbF levels nearly 4 times higher than African American patients and twice as high as Saudi Arabs with the Benin haplotype.(15) Even with an HbF of 15% to 20%, painful episodes, acute chest syndrome, and osteonecrosis were nearly as common in adults…”
Self-citationThe risks and benefits of long-term use of hydroxyurea in sickle cell anemia: a 17.5 year follow-up
Steinberg, M. H., McCarthy, W. F., Castro, O., Ballas, S. K., Armstrong, F. D., Smith, W., Ataga, K., Swerdlow, P., Kutlar, A., DeCastro, L., et al. (2010) · American Journal of Hematology · doi:10.1002/ajh.21699 · Cited by 486
Self-citationMortality in Sickle Cell Disease
(1994) · New England Journal of Medicine · doi:10.1056/nejm199410133311515 · Cited by 459
Hemoglobin S gelation and sickle cell disease
Eaton, W., & Hofrichter, J. (1987) · Blood · doi:10.1182/blood.v70.5.1245.1245 · Cited by 425 · cited 1×
“This effect of HbF is a result of a reduction of mean cell HbS concentration, a prime determinant of polymerization tendency, and because neither HbF nor its mixed hybrid tetramer (}2b g) can enter the deoxyHbS polymer phase.(1) From ;85% of total hemoglobin at birth, HbF normally falls to,1% at 1 year of age, with a…”
Fetal hemoglobin in sickle cell anemia: determinants of response to hydroxyurea
Steinberg, M. H., Lu, Z.-H., Barton, F. B., Terrin, M. L., Charache, S., Dover, G. J., & Hydroxyurea, T. M. S. O. (1997) · Blood · doi:10.1182/blood.v89.3.1078 · Cited by 407 · cited 2×
“The HbF response to hydroxyurea is variable: some patients do not respond to treatment; among responders, some achieve very high HbF levels and others do not.(5) Hydroxyurea does not For personal use only.”
Self-citationCorrection of Sickle Cell Disease in Adult Mice by Interference with Fetal Hemoglobin Silencing
Xu, J., Peng, C., Sankaran, V. G., Shao, Z., Esrick, E. B., Chong, B. G., Ippolito, G. C., Fujiwara, Y., Ebert, B. L., Tucker, P. W., et al. (2011) · Science · doi:10.1126/science.1211053 · Cited by 326 · cited 1×
“3% in control animals.(26) Whether or not targeting BCL11A or its pathway in humans will result in a pancellular or heterocellular distribution of HbF among erythrocytes is unknown.”
Cited by
Piel, F. B., Steinberg, M. H., & Rees, D. C. (2017) · New England Journal of Medicine · doi:10.1056/nejmra1510865 · Cited by 1,488
Self-citationKato, G. J., Piel, F. B., Reid, C. D., Gaston, M. H., Ohene-Frempong, K., Krishnamurti, L., Smith, W. R., Panepinto, J. A., Weatherall, D. J., Costa, F. F., et al. (2018) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2018.10 · Cited by 1,501
Intravascular hemolysis and the pathophysiology of sickle cell disease
Kato, G. J., Steinberg, M. H., & Gladwin, M. T. (2017) · Journal of Clinical Investigation · doi:10.1172/jci89741 · Cited by 748
Self-citationPiel, F. B., Steinberg, M., & Rees, D. C. (2016) · Spiral (Imperial College London) · doi:10.1056/nejmc1706325#sa6 · Cited by 659
Self-citationPost-Transcriptional Genetic Silencing of BCL11A to Treat Sickle Cell Disease
Esrick, E. B., Lehmann, L. E., Biffi, A., Achebe, M., Brendel, C., Ciuculescu, M. F., Daley, H., MacKinnon, B., Morris, E., Federico, A., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2029392 · Cited by 449
Metadata
- Authors
- Steinberg, M. H., Chui, D. H. K., Dover, G. J., Sebastiani, P., & Alsultan, A.
- Affiliations
- Boston University (US)
- Johns Hopkins University (US)
- Department of Biostatistics, Boston University School of Public Health, Boston, MA; and
- King Saud University (SA)
- Venue
- Blood
- Publisher
- American Society of Hematology
- Published
- 2014-01-23
- Volume
- 123
- Issue
- 4
- Pages
- 481-485
- ISSN
- 0006-4971 (ISSN-L)
- 1528-0020
- OpenAlex
- W2155090266
- Semantic Scholar
- 32a0bc6f2bf1ab756c92d813d957373aea130b2d
- Cited by
- 267
- References
- 26
- Citations by year
- 2026: 22 · 2025: 27 · 2024: 29 · 2023: 17 · 2022: 21 · 2021: 21 · 2020: 31 · 2019: 15 · 2018: 19 · 2017: 24 · 2016: 14 · 2015: 17 · 2014: 10
- FWCI
- 6.73
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Blood (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Genetics (clinical) › Hemoglobinopathies and Related Disorders
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Hemoglobin structure and function
- Health Sciences › Medicine › Hematology › Blood groups and transfusion
- Keywords
- fetal hemoglobin, sickle cell disease, hemoglobin S polymerization, F cells, disease phenotypes
- MeSH terms
- Adult, Anemia, Sickle Cell, Erythrocytes, Fetal Hemoglobin, Multigene Family, Haplotypes, Hemoglobin, Sickle, Heterozygote, Humans, Hydroxyurea, Models, Theoretical, Phenotype, Polymers, Gene Deletion
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Fetal hemoglobin in sickle cell anemia: a glass half full? https://app.cochat.ai/papers/10.1182/blood-2013-09-528067
- The paper
- Steinberg, M. H., Chui, D. H. K., Dover, G. J., Sebastiani, P., & Alsultan, A. (2014). Fetal hemoglobin in sickle cell anemia: a glass half full? Blood. https://doi.org/10.1182/blood-2013-09-528067
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.